China NMPA Drug Inspection - Qinghai Geladandong Pharmaceutical Co., Ltd. - Yifei Capsules

The Qinghai Provincial Food and Drug Administration, operating under China's National Medical Products Administration (NMPA) framework, issued an announcement on March 20, 2017, detailing findings from drug sampling inspections conducted throughout 2016. These inspections aimed to strengthen drug quality supervision and ensure public medication safety. The regulatory body identified several pharmaceutical companies with non-compliant products. Qinghai Dimaer Tibetan Medicine Pharmaceutical Co., Ltd.'s product, Shiwei Doukou Wan, was found to exceed microbial limits. Qinghai Jiumei Tibetan Medicine Pharmaceutical Co., Ltd. had two products failing quality standards: Ershiliuwei Tongjing Capsules exhibited issues with the content determination of Oleanolic Acid, and Zhenbao Jiedu Capsules failed content determination for Eucinol. Furthermore, Qinghai Geladandong Pharmaceutical Co., Ltd.'s Yifei Capsules also failed microbial limits testing. The primary violations involved critical quality parameters, specifically microbial contamination and inaccurate content determination of active pharmaceutical ingredients. While the document's explicit